CHICAGO — Garetosmab reduced new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva at 56 weeks compared with placebo, according to results of the OPTIMA trial presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results